Source: AMA Morning Rounds 7/29/2010
Wednesday, August 4, 2010
Multilayered efficiency system saves Denver health money, jobs. The Denver Post (7/29, Auge) reports that "a multilayered efficiency system known as Lean...has swept through Denver Health over the past five years with the fervor of a religious conversion." And "in an era marked by soaring healthcare costs and epidemic layoffs, even as it serves more and more uninsured patients while public funding dwindles, Denver Health has saved money and jobs -- and improved patient care -- using decades-old Toyota practices" emphasizing cost-cutting and high-quality, consistent work. "Since its Lean conversion in 2005, the city's public health system has benefited to the tune of $54 million in increased revenue, money not spent and expenses cut, according to chief financial officer Peg Burnette."
Source: AMA Morning Rounds 7/29/2010
Sunday, March 21, 2010
New reports suggest many Americans are being overtreated
Source: AMA Morning Rounds 3/15/2010
New reports suggest many Americans are being overtreated.
Sunday, November 29, 2009
New law bans genetic discrimination.
Source: AMA Morning Rounds 11/23/09
New law bans genetic discrimination.
The Los Angeles Times (11/22, Markman) reported that the Genetic Information Nondiscrimination Act, which has been called "the most sweeping federal anti-discrimination law in nearly 20 years," went into effect over the weekend. The law prohibits employers "from hiring, firing or determining promotions based on genetic makeup," and also forbids health insurers from using genetics as a basis for denying coverage or setting insurance rates. The law comes despite a number of concerns from insurers and the National Federation of Independent Business, who expressed concerns that employers could be held liable for having genetic information in their files.
In an editorial, the New York Times (11/22, WK9) opined that the law "is an important step in protecting people who have inherited a predisposition to disease," and "removes a significant obstacle to genetic testing." They note the objections made by insurance companies and business groups, and say that the law was passed regardless "because lawmakers rightly saw that fairness and public policy arguments demanded a ban on discriminating against people for genetic traits they can do nothing about."
Friday, June 26, 2009
Tobacco, Public Health, and the FDA
Tobacco, Public Health, and the FDA
Gregory D. Curfman, M.D., Stephen Morrissey, Ph.D., and Jeffrey M. Drazen, M.D.
Published at www.nejm.org June 22, 2009 (10.1056/NEJMe0905622)
More than a decade ago, David Kessler, then Commissioner of the Food and Drug Administration (FDA), launched a bold initiative to regulate tobacco. He believed that since nicotine is an addictive substance, it fell under the statutory authority of the FDA to regulate it as a drug and cigarettes as the delivery vehicle.
His effort failed, however, when the U.S. Supreme Court decided in a 5-to-4 ruling (FDA v. Brown & Williamson Tobacco Corp.) that the Food, Drug, and Cosmetic Act of 1938, which defined the FDA's authority, did not grant the agency jurisdiction to regulate tobacco. Writing for the Court, Justice Sandra Day O'Connor concluded that "it is plain that Congress has not given the FDA the authority to regulate tobacco products."1 The Court's decision was based on its reading of the statutory language in the act, not on what was best for the health of the public.
Today, President Barack Obama changed all that. With the signing of the Family Smoking Prevention and Tobacco Control Act of 2009, which was passed by sizable majorities in both the House and the Senate (and which we endorsed), the FDA has been given broad authority to regulate tobacco products. We believe that this historic legislation can have an unparalleled positive impact on the health of the American public.
The act establishes the Center for Tobacco Products, a unit within the FDA that will be funded by user fees from tobacco manufacturers and importers — $235 million in fiscal year 2010, rising to $712 million over the next 10 years. The center is charged with regulating tobacco products for the explicit purpose of protecting the health of the public. The FDA will now have the authority to require that all ingredients, compounds, and additives in tobacco products be reported to the agency, and those found to have harmful health effects may be banned. Nicotine levels in cigarettes may be regulated, but neither nicotine nor cigarettes may be banned outright. In keeping with the act's focus on protecting those under 18 years of age, flavorings in cigarettes, which are meant to appeal to young smokers, are banned, with the exception of menthol, which could be banned later if found to be a health hazard. No new tobacco product can be marketed unless first approved by the FDA.
Importantly, the act will also allow regulation of so-called modified risk tobacco products, which are typically identified by terms on the package such as "light," "low," or "mild." The use of such terms will no longer be permitted unless the product has been shown to significantly reduce harm. Warning labels on cigarette packages will be made more graphic and will require the use of color. Tobacco companies may no longer sponsor sporting events.
For the first time in almost 40 years, state and local governments will be allowed to regulate the marketing of tobacco, establishing restrictions that may be more rigorous than those of the FDA. In addition, the act requires that the 1996 Tobacco Rule, which was put in place by Commissioner Kessler and deemed unconstitutional by the Supreme Court, must be reinstated. This rule places restrictions on tobacco advertising, including a ban on outdoor advertising within 1000 ft of a school. It is anticipated that this regulation may be the focus of a constitutional challenge on the basis that such advertising represents commercial speech subject to First Amendment protection. Still, there is good reason to believe that this carefully crafted provision, which is narrowly tailored to focus on smoking prevention in the nation's young, will survive any such legal challenge.
The long-term impact of the Family Smoking Prevention and Tobacco Control Act on the health of the public will depend critically on its implementation through strict regulations, rigorously enforced. FDA Commissioner Margaret Hamburg and Principal Deputy Commissioner Joshua Sharfstein promise to be strong advocates for rigorous enforcement.
In a recent article in the Journal, Hamburg and Sharfstein laid out their new mission.2 They regard the FDA as a public health agency whose purpose is not just to regulate the nation's food and drug supplies, but to protect the health of American citizens. Hamburg has also indicated that she is eager to undertake the regulation of tobacco and said in an interview, "We now have an opportunity to really make a difference with what is probably the No. 1 public health concern in the nation and the world."3
Few threats to the health of the public are as onerous as tobacco. Each year more than 435,000 Americans die of tobacco-related illnesses, principally heart, vascular, and lung diseases. Tobacco use is also associated with substantial morbidity and diminished quality of life. More than one in five Americans still smoke, an astonishing figure given the overwhelming evidence of harm. In addition to excess morbidity and mortality, tobacco adds considerably to health care costs at a time when reducing costs is a national priority. The total annual health care expenditures caused by smoking run to $96 billion.4 Along with other critical prevention goals, such as controlling obesity and increasing levels of physical activity, the elimination of cigarette smoking is central to improving the health of our citizens and mitigating the growth of health care costs.
The Family Smoking Prevention and Tobacco Control Act of 2009 comes at a propitious moment in U.S. history. We strongly support the FDA's new leaders and urge them to implement the act aggressively. As a medical journal, we are committed to eliminating the public health threat tobacco represents to American society and the world.
Source Information
This article (10.1056/NEJMe0905622) was published on June 22, 2009, at NEJM.org.
References
FDA v. Brown & Williamson Tobacco Corp. 529 U.S. 120 (2000).
Hamburg MA, Sharfstein JM. The FDA as a public health agency. N Engl J Med 2009;360:2493-2495. [Free Full Text]
Harris G. New F.D.A. chief says she'll toughen enforcement efforts. New York Times. June 17, 2009:A19.
Campaign for Tobacco-free Kids. Toll of tobacco in the United States of America. April 2009. (Accessed June 22, 2009, at http://www.tobaccofreekids.org/research/factsheets/pdf/0072.pdf.)
Monday, March 23, 2009
“Fat taxes” and the financial crisis
“Fat taxes” and the financial crisis
The most controversial aspect of the “fat tax” debate is that any new tax on unhealthy foods is likely to hit poorest groups hardest. A “fat tax” would be regressive—in other words, low-income households would spend a higher proportion of their income on the tax than higher income households. The potential effect of New York's proposed “soda tax” on the state's poorest citizens, for example, has been heavily criticised. “The Governor of New York announced a few weeks ago that he was not going to impose any taxes on the rich. Yet the same governor seems to have no qualms imposing regressive taxes on the African American poor”, said Adam Drewnowski, director of the University of Washington's Center for Obesity Research. “If you look at the map of soft drinks consumption in NYC and the map of poverty you will see that they are—in fact—one and the same.”
AIM: End-of-life discussions drive down treatment costs, improve quality of life
| AIM: End-of-life discussions drive down treatment costs Daily Briefing - The Advisory Board Company03/11/2009 |
| Terminally ill patients who discussed end-of-life (EOL) care with their physicians had significantly lower health care costs and were more likely to have a better quality of life (QOL) in their final week of life compared with patients who did not have these conversations, according to a study published this week in the Archives of Internal Medicine (AIM). For the study, researchers from the Boston-based Dana-Farber Cancer Institute and colleagues followed a cohort of 627 patients with advanced cancer who were recruited for the longitudinal, multi-institutional Coping With Cancer Study between September 2002 and December 2007. At baseline—on average, six months before death—188 of 603 participants reported they had EOL discussions with their physicians. According to the findings, patients who had these discussions were more likely than their counterparts to acknowledge that they were terminally ill and report a desire to avoid dying in an ICU; patients who had EOL discussions were also less likely to prefer that their physicians take aggressive measures to extend life for a few days. As a result, the cost of care in the final week of life for patients who had discussed EOL goals with physicians averaged 35.7% lower (at an average of $1,876) than the cost of care for patients who did not have an EOL dialogue with their physicians, whose care during their final weeks of life averaged $2,917, according to aggregate costs of care determined using data from the 2004 Nationwide Inpatient Sample. Additionally, higher costs of treatment in the final week of life were not associated with better outcomes; rather, high-cost patients experienced a worse quality of death, as reported by their caregivers. Noting that 30% of annual Medicare expenditures are attributed to the 5% of beneficiaries who die, and that about one-third of the expenditures in the last year of life are spent in the last month—mostly on life-sustaining care—the study’s authors suggest that EOL discussions between patients and providers may be an effective approach to curtailing medical care expenditures while improving patients’ quality of life and death. Specifically, the authors assert that if the “national proportion of individuals reporting EOL discussions” with health care providers increased to 50%, the cost difference between EOL and non-EOL patients could top $76 million nationally, based on the total number of U.S. cancer deaths annually. To that end, the authors support the adoption of strategies to “promote increased communication,” including direct reimbursement for EOL discussions, improved physician education regarding EOL communication, and expansion of hospital palliative care programs. Additionally, the authors suggest that oncologists and palliative care physicians co-manage care of patients with late-stage cancer. |
| STUDY FINDS END-OF-LIFE COSTS HIGHER AMONG BLACK, HISPANIC PATIENTS |
| In another study published in AIM, researchers from the Boston University School of Medicine and colleagues analyzed records of of more than 158,000 Medicare beneficiaries who died in 2001, finding that black and Hispanic patients have substantially higher EOL costs than white patients. Specifically, the mean cost of care for white patients averaged $20,166 across the last six months of life, compared with $26,704 for black patients and $31,702 for Hispanic patients. Although the study did not examine the direct cause of treatment cost disparities, the researchers attributed nearly 85% of the higher costs for non-white patients to greater use of ICU care and intensive procedures. According to the CMO of the American Cancer Society, higher utilization of life-extending procedures among minority patients may stem in part from the fact that minority populations are less likely to receive preventive care and establish long-term relationships with physicians (Zhang et al., AIM, 3/9 [subscription required]; Hanchate et al., AIM, 3/9 [subscription required]; Tanner, Associated Press/Los Angeles Times, 3/9; Stern, Reuters, 3/9; Smith, MedPage Today, 3/9). |
Thursday, March 19, 2009
Task force revises aspirin guidelines for heart attack, stroke
Task force revises aspirin guidelines for heart attack, stroke
Cardiovascular Business
Wednesday March 18, 2009
The U.S. Preventive Services Task Force has recommended aspirin use for primary prevention of heart attack and stroke in the March 17 issue of the Annals of Internal Medicine, citing its improved specificity over previous guidelines.
The task force found that men between the ages of 45 and 79 should use aspirin to reduce their risk for heart attacks when the benefits outweigh the harms for potential gastrointestinal bleeding. Women between the ages of 55 and 79 should use aspirin to reduce their risk for ischemic stroke when the benefits outweigh the harms for potential gastrointestinal bleeding.
However, the task force was against the use of aspirin for stroke prevention in women younger than 55 years and for MI prevention in men younger than 45 years.
"The task force has taken positive steps to lend clarity to patients and physicians about the value of aspirin for prevention of cardiovascular events," said American College of Preventive Medicine (ACPM) President Mark B. Johnson, MD. "The new guidelines make it clear that physicians, as a matter of routine practice, should be discussing the pros and cons of daily aspirin use with patients in the target groups."
An ACPM-sponsored survey published in the May 2007 edition of the American Journal of Preventive Medicine found a conversation between the patient and physician to be the strongest predictor of appropriate aspirin use, and that only about one in three patients who are at high risk are actually taking daily aspirin. A separate study by the Partnership for Prevention found that 45,000 lives could be saved each year if 90 percent of the target population took a low-dose aspirin every day. The studies led the American Medical Association (AMA) to adopt a policy to increase education among physicians on the importance of appropriate aspirin counseling.
With the release, the UPSTF updates its aspirin recommendations from 2002, which called on clinicians to discuss aspirin use for primary prevention with adults who are at increased risk for cardiovascular disease. The new USPSTF findings actually recommend aspirin use where benefits outweigh the harms, and further define the appropriate age and gender groupings for which aspirin is indicated.
"We think the new guidelines provide another tool in the armamentarium of the physician and the patient for assuring that a discussion about cardiovascular risk and potential aspirin use routinely takes place in the clinical setting," said David Shih, MD, senior director of medical affairs at ACPM.
Last Updated ( Thursday, March 19 2009 )
Wednesday, March 18, 2009
Religious Belief Linked to Desire for Aggressive Treatment in Terminal Patients
Religious Belief Linked to Desire for Aggressive Treatment in Terminal Patients
Terminally ill cancer patients who drew comfort from religion were far more likely to seek aggressive, life-prolonging care in the week before they died than were less religious patients and far more likely to want doctors to do everything possible to keep them alive, a study has found.
The patients who were devout were three times as likely as less religious ones to be put on a mechanical ventilator to maintain breathing during the last week of life, and they were less likely to do any advance care planning, like signing a do-not-resuscitate order, preparing a living will or creating a health care proxy, the analysis found.
The study is to be published Wednesday in The Journal of the American Medical Association.
“People think that spiritual patients are more likely to say their lives are in God’s hands — ’Let what happens happen’ — but in fact we know they want more aggressive care,” said Holly G. Prigerson, the study’s senior author and director of the Center for Psychosocial Oncology and Palliative Care Research at the Dana-Farber Cancer Institute in Boston.
“To religious people, life is sacred and sanctified,” Dr. Prigerson said, “and there’s a sense they feel it’s their duty and obligation to stay alive as long as possible.”
Aggressive life-prolonging care comes at a cost, however, in terms of both dollars and human suffering. Medicare, the government’s health plan for the elderly, spends about one-third of its budget on people who are in the last year of life, and much of that on patients at the very end of life.
Aggressive end-of-life care can lead to a more painful process of dying, researchers have found, and greater shock and grief for the family members left behind.
The new study used both a questionnaire and interviews to assess the level of reliance on religious faith for comfort among 345 patients with advanced cancer. The patients, most of them belonging to Christian denominations, were followed until they died, about four months on average.
A vast majority of patients, religious or not, did not want heroic measures taken. Still, 11.3 percent of the most religious patients received mechanical ventilation during the last week of life, compared with only 3.6 percent of the least religious.
The most religious patients were also more likely than less religious ones to be resuscitated in the last week of life and to be treated in an intensive-care unit as they died, although those differences may have been due to chance.
“Doctors don’t always acknowledge, and I’m pretty sure patients are telling us, that God is really important in their lives,” said Dr. Gerard Silvestri, a cancer specialist at the Medical University of South Carolina in Charleston, S.C., who has studied end-of-life decision making.
A study by Dr. Silvestri in 2003 found that while cancer patients listed their oncologist’s recommendation as the most influential factor affecting their decisions about medical care, their faith in God was the second-most-influential factor, ranking higher than the recommendations of their family doctors, their spouses and children, and even information about whether treatment would cure the disease.
Prostate Cancer Test Found to Save Few Lives
Prostate Cancer Test Found to Save Few Lives
By GINA KOLATAThe PSA blood test — the screening test for prostate cancer — saves few if any lives and exposes large numbers of men to risky and unnecessary treatment, two large and rigorous studies have found.
The findings raise new questions about the rapid and widespread adoption of the test, which measures a protein released by prostate cells. It was introduced in 1987 and quickly became a routine part of preventive health care. Experts debated its value, basing their views on data that often involved statistical modeling and inferences.
Now, with the new data, cancer experts said men should carefully consider the test’s risks and benefits before deciding to be screened. Some may decide not to be screened at all.
The studies, said Dr. Otis Brawley, the chief medical officer at the American Cancer Society, are “some of the most important studies in the history of men’s health.”
For years, the cancer society has urged men to be informed before deciding to have a PSA test. “Now we actually have something to inform them with,” he said. “We’ve got numbers.”
Dr. H. Gilbert Welch, a professor of medicine at Dartmouth who studies cancer screening, also welcomed the new data. “We’ve been waiting years for this,” he said. “It’s a shame we didn’t have it 20 years ago.”
Both reports were published online on Wednesday by The New England Journal of Medicine. One involved 182,000 men in seven European countries; the other, by the National Cancer Institute, involved nearly 77,000 men at 10 medical centers in the United States.
In both, participants were randomly assigned to be screened — or not — with the PSA test, whose initials stand for prostate-specific antigen. In each study, the two groups were followed for more than a decade while researchers counted deaths from prostate cancer, asking whether screening made a difference.
The European data involved a consortium of studies with different designs. Taken together, the studies found that screening was associated with a 20 percent relative reduction in the prostate cancer death rate. But the number of lives saved was small — seven fewer prostate cancer deaths for every 10,000 men screened and followed for nine years.
The American study, which had a single design, found no reduction in deaths from prostate cancer after most of the men had been followed for 10 years. Every man has been followed for at least seven years, said Dr. Barnett Kramer, a study co-author at the National Institutes of Health. By seven years, the death rate was 13 percent lower for the unscreened group.
The European study saw no benefit of screening in the first seven years of follow-up.
The reason screening saved so few lives, cancer experts say, is that prostate cancers often grow very slowly, if at all, and most never endanger a man if left alone. But when doctors find an early-stage prostate tumor, they cannot tell with confidence whether it will be dangerous so they usually treat all early cancers as if they were life-threatening.
As a result, the majority of men, whose early-stage cancers would not harm them, suffer serious effects of cancer therapy but get no benefit. Others, with very aggressive tumors, may not be helped by screening because their cancer has spread by the time it is detected.
Prostate cancer is not the only one that is hard to stop with screening. If the European study is correct, mammography has about the same benefit as the PSA test, said Dr. Michael B. Barry, a prostate cancer researcher at Massachusetts General Hospital who wrote an editorial accompanying the papers. But prostate cancers often are less dangerous than breast cancers, so screening and subsequent therapy can result in more harm.
In the European study, 48 men were told they had prostate cancer, and needlessly treated for it, for every man whose death was prevented. With mammography, about 10 women receive a diagnosis and needless treatment for breast cancer to prevent one death.
Dr. Peter B. Bach, a physician and epidemiologist at Memorial Sloan-Kettering Cancer Center, says one way to think of the data is to suppose he has a PSA test today. It leads to a biopsy that reveals he has prostate cancer, and he is treated for it. There is a one in 50 chance that, in 2019 or later, he will be spared death from a cancer that would otherwise have killed him. And there is a 49 in 50 chance that he will have been treated unnecessarily for a cancer that was never a threat to his life or health.
Prostate cancer treatment can result in impotence and incontinence when surgery is used to destroy the prostate, and painful defecation or chronic diarrhea when the treatment is radiation.
When the American and European studies began, in the early 1990s, PSA testing was well under way in the United States, and many expected that the screening test would make the prostate cancer death rate plummet by 50 percent or more. Dr. Brawley was at the cancer institute then, though not directly involved with its prostate cancer screening study. But he saw the reactions.
Some urologists said the study was unethical, because some people would not be screened, and demanded it be shut down, he said. One group of black urologists encouraged black men not to participate because blacks have a greater risk of prostate cancer and it seemed obvious they should be screened.
Some thought that they would see fewer cancer deaths among the screened men as quickly as five years. But as the studies continued, it became clear that screening would not have a large, immediate effect — if it did, the studies would have been stopped and victory declared. Cancer researchers began turning to less rigorous sources of data, with some arguing that screening was preventing prostate cancer deaths and others arguing it was not.
In the United States, many men and their doctors have made up their minds — most men over age 50 have already been screened, and each year more than 180,000 receive a diagnosis of prostate cancer. In Europe, said Dr. Fritz H. Schröder of Erasmus University, the lead author of the European study, most men are not screened. “The mentality of Europeans is different,” he said, and screening is not so highly promoted.
The publication, of data from the two studies should change the discussion, said Dr. David Ransohoff, an internist and cancer epidemiologist at the University of North Carolina.
“This is not relying on modeling anymore,” Dr. Ransohoff said. “This is not some abstract, pointy-headed exercise. This is the real world and this is real data.”
Both studies will continue to follow the men. It remains possible that the United States study will eventually find that screening can reduce the prostate cancer death rate, researchers say, or that both studies will conclude that there is no real reduction.
In the meantime, Dr. Brawley said, “I certainly think there’s information here that’s food for thought.”
The benefits of prostate cancer screening, he said, are “modest at best and with a greater downside than any other cancer we screen for.”Web Link
Mortality Results from a Randomized Prostate-Cancer Screening Trial (The New England Journal of Medicine)
Screening and Prostate-Cancer Mortality in a Randomized European Study (The New England Journal of Medicine)
Tuesday, March 3, 2009
HealthGrades releases annual list of ‘America’s 50 Best Hospitals’
| 02/25/2009 |
| HealthGrades yesterday released its annual list of “America’s 50 Best Hospitals,” which includes facilities that have ranked among the top 5% of the nation’s hospitals on clinical outcomes measures for at least the past six years across 26 common procedures and conditions. To create the list, researchers from the independent health care ratings organization reviewed more than 110 million hospitalization records that all non-federal U.S. hospitals—nearly 5,000 in total—submitted to CMS between fiscal years 1999 and 2007. After risk-adjusting the data to account for differences in patient populations among hospitals, HealthGrades compared facilities’ mortality and complication rates across the selected procedures and diagnoses, including spinal fusion, coronary bypass surgery and interventional procedures, myocardial infarction, heart failure, pneumonia, sepsis, and stroke, among others. To qualify for inclusion in the analysis, hospitals had to meet minimum thresholds for patient volumes, quality ratings, and the range of services provided. In releasing its 11th annual list—which includes 30 hospitals concentrated in just the four states of California, Florida, Ohio, and Pennsylvania—HealthGrades said that the top 50 hospitals had achieved mortality and complication rates that were approximately 27% and 8% lower, respectively, than those at all other U.S. hospitals. Examining the 2009 list, the Washington Post notes the omission of “several hospitals…that appear on most lists of the nation’s best,” adding that variation in different organizations’ ranking methodologies ultimately results “in wide variance from one list to the next.” Acknowledging that the exclusion of certain academic medical centers from HealthGrades’ top 50 “always calls into question the validity of this sort of list,” the company’s chief medical officer emphasizes that the HealthGrades list uses “a window based purely on outcomes” for 26 procedures and conditions, adding that many major medical centers’ reputations reflect their expertise across a broad range of specialties, including conditions and procedures beyond the scope of HealthGrades’ analysis (Halsey III, Washington Post, 2/25 [registration required]; HealthGrades release, 2/24). To view the complete “America’s 50 Best Hospitals” list, please visit the HealthGrades website at www.healthgrades.com. |
Thursday, January 22, 2009
The Joint Commission to Include Patient Satisfaction Data on Quality Check™
January 20, 2009
The Joint Commission to Include Patient Satisfaction Data on Quality Check™
Web site provides new information to help patients make decisions
Media Contact: Ken PowersMedia Relations Manager630-792-5175kpowers@jointcommission.org
(OAKBROOK TERRACE, Ill. – January 20, 2009) People seeking information about how patients perceive the care they received at a particular hospital can now find this information on The Joint Commission’s Quality Check™ Web site, http://www.qualitycheck.org/.
The Hospital Consumer Assessment of Health Providers and Systems (HCAHPS) data from the Centers for Medicare & Medicaid Services’ (CMS) Hospital Compare Web site is posted on Quality Check™ beginning this month. This information will be updated quarterly.
HCAHPS information comes from patient ratings of communication with doctors, communication with nurses, responsiveness of hospital staff, cleanliness and quietness of the hospital, pain management, communication about medications, and discharge information. In addition to information about patient satisfaction, Quality Check™ also includes data from CMS on 30-day mortality rates for heart attack, heart failure and pneumonia.
Thousands of people use Quality Check™ each month to find information about the more than 15,000 accredited health care organizations that have earned The Joint Commission “Gold Seal of Approval.” Quality Check™ provides details about an organization’s accreditation status, efforts to prevent medical mistakes by complying with National Patient Safety Goals, and comparison information about how hospitals comply with National Quality Improvement Goals such as giving heart attack patients aspirin within a specified timeframe.
Wednesday, January 21, 2009
How should Obama reform health care?
http://www.newyorker.com/reporting/2009/01/26/090126fa_fact_gawande?printable=true
Annals of Public Policy
Getting There from Here: How should Obama reform health care?
by Atul Gawande
Our jerry-rigged health-care system contains many models that reformers can build on.
(exerpt)
In every industrialized nation, the movement to reform health care has begun with stories about cruelty. The Canadians had stories like the 1946 Toronto Globe and Mail report of a woman in labor who was refused help by three successive physicians, apparently because of her inability to pay. In Australia, a 1954 letter published in the Sydney Morning Herald sought help for a young woman who had lung disease. She couldn’t afford to refill her oxygen tank, and had been forced to ration her intake “to a point where she is on the borderline of death.” In Britain, George Bernard Shaw was at a London hospital visiting an eminent physician when an assistant came in to report that a sick man had arrived requesting treatment. “Is he worth it?” the physician asked. It was the normality of the question that shocked Shaw and prompted his scathing and influential 1906 play, “The Doctor’s Dilemma.” The British health system, he charged, was “a conspiracy to exploit popular credulity and human suffering.”